Investigating how MED1 affects androgen receptor activity in advanced prostate cancer
Role of MED1 in the AR-dependent transcription in advanced prostate cancer
This study is looking at how a protein called MED1 affects the growth of advanced prostate cancer that doesn't respond to usual treatments, with the hope of finding new ways to help patients by testing a drug that targets a specific enzyme involved in this process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10832513 on NIH RePORTER |
What this research studies
This research focuses on advanced metastatic castration-resistant prostate cancer (CRPC), a severe form of cancer that often becomes resistant to standard treatments. The study aims to understand the role of a protein called MED1 in the regulation of androgen receptor (AR) signaling, which is crucial for the growth of this cancer type. By examining how MED1 interacts with AR and how its phosphorylation by a specific kinase (CDK7) influences this interaction, the researchers hope to identify new therapeutic strategies. The ultimate goal is to evaluate the effectiveness of CDK7 inhibitors in reversing the dependency of CRPC on AR signaling, potentially leading to improved treatment options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced metastatic castration-resistant prostate cancer who have developed resistance to anti-androgen therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone anti-androgen treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target and inhibit the growth of advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting androgen receptor signaling in prostate cancer, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Asangani, Irfan Ahmed — University of Pennsylvania
- Study coordinator: Asangani, Irfan Ahmed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.